NCT04438096 - Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

December 15, 2021

Study Completion Date

March 15, 2022

Conditions

Hyperlipidemia

Interventions

DRUG

100 mg

One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks

DRUG

200 mg

Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks

DRUG

300 mg

Three 100 mg pills (QD) will be orally administered for 12 weeks

DRUG

Placebo

Three placebo pills (QD) will be orally administered for 12 weeks

Trial Locations (1)

RECRUITING

The second affiliated hospital of zhejiang University school of medicine, Hangzhou